Your session is about to expire
← Back to Search
Digital Inhalers for Asthma
Study Summary
This trial is being done to see how well patients with asthma respond to treatment with TEVA digital inhalers. Data from these devices will be used to help predict asthma exacerbations and response to biologics.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a significant lung condition other than asthma.My asthma control score is below 19, indicating poor control.My health condition is stable and won't affect my participation in the study.I am willing to change my inhalers to AirDuo and ProAir Digihaler.I do not have any severe illnesses that could stop me from completing a 12-month study.I have severe asthma that hasn't improved with strong asthma medications.You have a history of drinking too much alcohol or using drugs regularly.I am currently using or plan to use biologic therapy after joining the study.I have HIV or another immune system condition.I have had a cancer, other than skin cancer, in the past year that affects my survival.
- Group 1: AirDuo and ProAir
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical condition is AirDuo Digihaler typically employed to address?
"The AirDuo Digihaler is prescribed to those suffering from bronchodilator agents, as well as rhinorrhoea, seasonal allergic rhinitis and chronic bronchitis."
Has the AirDuo Digihaler been granted authorization from the FDA?
"AirDuo Digihaler has been approved by the relevant governing bodies, so it is rated 3 out of 3 on our safety scale."
Are there currently any spots available for enrollment in this clinical trial?
"Affirmative. The information hosted on clinicaltrials.gov indicates that this medical experiment, which was initially announced on July 9th 2021, is at present looking for participants. A total of 100 patients will be enrolled from a single site."
Can you tell me more about the past studies conducted on AirDuo Digihaler?
"Currently, there are 26 medical trials being conducted to evaluate the efficacy of AirDuo Digihaler. Two of these studies have reached Phase 3 and most take place in Ann Arbor, Michigan. Across all 88 sites running this trial, patients can participate."
What is the total enrollment of this trial?
"Affirmative. Clinicaltrials.gov data shows that the study, first introduced on July 9th 2021, is currently recruiting patients. The project seeks to find 100 volunteers from a single medical centre."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger